After having warned that it could lose up to 94% of its staff in a relocation from its current home in London, United Kingdom, The European Medicines Agency (EMA) this week revealed its top location choices for the agency’s upcoming move.
After having warned that it could lose up to 94% of its staff in a relocation from its current home in London, United Kingdom, The European Medicines Agency (EMA) this week revealed its top location choices for the agency’s upcoming move.
The EMA rated each of the cities proposing to host the agency in terms of technical requirements (including building layouts and relocation planning), additional criteria (including accessibility of each location, resources for families of staffers, and business continuity), and the likelihood of retaining the most personnel. Vying for the EMA are Amsterdam, Netherlands; Athens, Greece; Barcelona, Spain; Bonn, Germany; Bratislava, Slovakia; Brussels, Belgium; Bucharest, Romania; Copenhagen, Denmark; Dublin, Ireland; Helsinki, Finland; Lille, France; Malta; Milan, Italy; Porto, Portugal; Sofia, Bulgaria; Stockholm, Sweden; Vienna, Austria; Warsaw, Poland; and Zagreb, Croatia.
The cities that earned top marks for meeting the EMA's technical requirements were the following:
Each of the above cities met some of the agency’s requirements, though the EMA had concerns about timely operation at each of the locations. Sofia and Malta earned the lowest ratings in this category.
In terms of its additional criteria, the EMA gave Vienna top marks, with Amsterdam, Barcelona, Copenhagen, Milan also ranked highly.
The cities in which the EMA was likely to retain 65% or more of its staff, based on feedback from its workers, were the following:
The cities where the agency could expect to retain less than 30% of its staff were the following:
While the EMA rated Barcelona highly in each of its categories, political unrest in Catalonia could take a toll on the city’s ability to secure the regulatory body's presence. Last week’s vote on independence for the Catalonia region was met with a show of Spanish police force that left hundreds of civilians injured. On Friday, Spain’s government began to ease restrictions on businesses seeking to leave Barcelona and other Catalonian areas in order to remain in the Eurozone in the event of a Catalonian secession; should Catalonia become an independent nation, it would not automatically retain membership in the European Union, and Barcelona could become just as untenable a long-term home for the EMA as London was.
The EMA has provided its report to the European Commission, which will determine the agency’s new location in a vote held next month.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.